Skip to main content

Search

Search the site:

News, Views, and Advocacy From the Oncology Nursing Society

News & Views

Advocacy

Stories

News & Views

Latest Articles
Clinical Practice
ONS News
ONS Leadership

Trending Topics

Research
Treatments
Safety
COVID-19
Drug Reference Sheet
Clinical practice

View All Topics

Advocacy

Latest Articles
Updates
Get Involved

Stories View All

View All

Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results

Pancreatic cancer

Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results

November 11, 2022

The Life of Marie Curie and Her Contributions to Oncology

Cancer treatments

The Life of Marie Curie and Her Contributions to Oncology

November 07, 2022

Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points

Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points

September 28, 2022

Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?

Radiation therapy

Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?

August 19, 2022

Without My Fellowship Program and ONS, I Would Not Be the Nurse I Am Today

Nurse empowerment

Without My Fellowship Program and ONS, I Would Not Be the Nurse I Am Today

Search

News & Views

Advocacy

Stories

Home

Author Content

Drug Reference Sheet

Oncology Drug Reference Sheet: Tebentafusp-Tebn

When the U.S. Food and Drug Administration approved tebentafusp-tebn (Kimmtrak®) in January 2022 as an orphan drug for unresectable or metastatic uveal melanoma in adults, it became the first—and only, at the time of this reference sheet’s publication—drug approved for the indication.

November 22, 2022

Clinical practice

Oncology Drug Reference Sheet: Fam-Trastuzumab Deruxtecan-Nxki

Bringing the first agent to market for the indication, on August 5, 2022, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu®) for patients with unresectable or metastatic HER2-low breast cancer based on results from the DESTINY-Breast04 trial that demonstrated improved progression-free and overall survival. FDA also gave fam-trastuzumab deruxtecan its fourth approval on August 11, 2022, for unresectable or metastatic HER2-activating non-small cell lung cancer (NSCLC).

October 07, 2022

What Is HER2-Low Breast Cancer?

Human epidermal growth factor receptor 2 (HER2) proteins are involved in normal cellular growth and are found on the surface of all breast cells. Approximately 20% of breast cancers are HER2 positive, meaning they have high levels of HER2 protein, and those cancers typically grow and metastasize more quickly than other types of breast cancer.

October 07, 2022

Nursing education

Monkeypox Fact Sheet and Implications for Patients With Cancer

In May 2022, the Centers for Disease Control and Prevention began tracking cases of monkeypox in the United States, a disease caused by infection with the monkeypox virus. As of August 2022, 48 U.S states have reported at least some level of monkeypox diagnoses, and the World Health Organization declared the virus a global public health emergency.

August 10, 2022

Drug Reference Sheet

Oncology Drug Reference Sheet: Loncastuximab Tesirine-Lpyl

Based on LOTIS-2 trial results that reported an overall response rate of nearly 50%, in April 2021 the U.S. Food and Drug Administration granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta^TM) for adults with relapsed or refractory large B-cell lymphoma.

Patient resources

What Patients and Oncology Nurses Need to Know About Vaccination and Cancer

People with cancer have a particular risk for infection, and vaccines can be a powerful preventive tool. According to the World Health Organization, immunization prevents 2–3 million deaths every year worldwide from diseases, including diphtheria, influenza, and measles. Here’s what patients and nurses need to know about vaccines and guidelines for people with cancer.

Drug Reference Sheet

Oncology Drug Reference Sheet: Ivosidenib

Adding to its earlier approvals for use in adults with acute myeloid leukemia (AML), on August 25, 2021, the U.S. Food and Drug Administration (FDA) approved ivosidenib (Tibsovo^®) for adults with previously treated, locally advanced or metastatic cholangiocarcinoma. Cholangiocarcinoma, or cancer of the bile ducts, is a rare cancer, and ivosidenib is the only currently approved agent for patients with an IDH1 variant.

January 25, 2022

Drug Reference Sheet

Oncology Drug Reference Sheet: Belantamab Mafodotin-Blmf

A first-of-its-kind antibody-drug conjugate for multiple myeloma, belantamab mafodotin-blmf (Blenrep) received accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2020. The approval was based on clinical trial findings that demonstrated a 31% overall response rate that lasted at least six months in 73% of responders.

October 26, 2021

Clinical practice

What Is a Liquid Biopsy?

All cells (healthy cells and tumor cells) in the body shed DNA, called cell-free DNA (cfDNA). When it’s only from tumor cells, it’s referred to as circulating tumor DNA (ctDNA), although cfDNA and ctDNA are sometimes used interchangeably.

October 25, 2021

Clinical practice

Oncology Drug Reference Sheet: Relugolix

On December 18, 2020, the U.S. Food and Drug Administration approved relugolix (Orgovyx^TM) as the first oral hormone therapy for use in adult patients with advanced prostate cancer.

Be Alert for Axillary Adenopathy After COVID-19 Vaccination

Nearly 60 million people in the United States and almost 200 million around the world have received the COVID-19 coronavirus vaccine as of mid-February 2021, and the numbers will continue to grow as more doses come to market and other manufacturers’ versions receive emergency use authorizations. As more people get vaccinated, some of the expected side effects are being observed in clinical practice and have implications for cancer care.

February 19, 2021

Oncology drug research

Oncology Drug Reference Sheet: Tafasitamab-Cxix

Tafasitamab-cxix (Monjuvi^®) received accelerated approval from the U.S. Food and Drug Administration in July 2020 in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma.

January 26, 2021

COVID-19 Reference Sheet: Vaccines

To control the COVID-19 coronavirus pandemic, society needs public health measures (e.g., masks, physical distancing, hand washing), treatments for infection, and vaccines to prevent infection or serious disease. As the most trusted profession, nurses have a responsibility to educate patients and the community about the facts and science behind the vaccines. This reference sheet will help guide those conversations and is regularly updated as new information is released.

December 14, 2020

Clinical practice

Oncology Drug Reference Sheet: Lurbinectedin

In June 2020, the U.S. Food and Drug Administration granted accelerated approval to lurbinectedin (Zepzelca^TM) for adults with metastatic small cell lung cancer (SCLC) whose disease has progressed on or after platinum-based chemotherapy. The approval adds a second choice for patients who experience treatment-resistant SCLC progression, who previously had only topotecan as an option.

October 20, 2020

U.S. Food and Drug Administration (FDA)

Oncology Drug Reference Sheet: Enfortumab Vedotin-Ejfv

Enfortumab vedotin-ejfv (Padcev™) was granted accelerated approval in December 2019 for adults with locally advanced or metastatic urothelial cancer who previously received an immune checkpoint inhibitor (PD-1 or PD-L1 inhibitor) and platinum-containing therapy.

A Perspective on COVID-19 for New and Student Nurses

COVID-19 coronavirus’s ripple effects extend so far beyond health and health care. Life in the United States doesn’t look the same as it did a few months ago. We’re all affected in some way, but senior nursing students have a distinct set of circumstances related to the pandemic.

Oncology Drug Reference Sheet: Tocilizumab

Tocilizumab was approved in August 2017 for the treatment of chimeric antigen receptor T cell–induced cytokine release syndrome. In March 2020, the U.S. Food and Drug Administration approved a randomized, double-blind, placebo-controlled, phase III clinical trial to assess the safety and efficacy of tocilizumab plus standard of care in patients hospitalized with severe COVID-19 pneumonia.

Clinical practice

Emotional Coping Strategies for COVID-19

The COVID-19 novel coronavirus pandemic is turning the world, inside and outside of the hospital, upside down. Not only are oncology nurses seeing high demands at work, but changes and restrictions are being instated at home as well.

Clinical practice

COVID-19 Fact Sheet and Implications for Patients With Cancer

COVID-19 is a novel coronavirus (a large family of viruses that can cause cold-like illnesses) first identified in December 2019. It is a respiratory illness and can be spread from person to person through respiratory droplets during close contact. The first case of COVID-19 in the United States was reported on January 21, 2020.

Oncology Drug Reference Sheet: Niraparib

Niraparib was approved in October 2019 for patients with homologous recombination deficiency (HRD)-positive advanced ovarian, fallopian tube, or primary peritoneal cancer.

February 25, 2020

Oncology Drug Reference Sheet: Radium 223 Dichloride

Radium 223 dichloride (Xofigo^®) is an alpha particle-emitting radioactive therapeutic agent approved by the U.S. Food and Drug Administration in 2013 for castrate-resistant prostate cancer.

December 24, 2019

Oncology nurse scientist

Beta Data Browser Puts Precision Medicine Cohort at Researchers’ Fingertips

The future of cancer care is here: precision medicine has led to many of today’s newest cancer treatments and has made incredible progress since former President Barak Obama first announced the U.S. Precision Medicine Initiative (PMI) in 2015.

Oncology Drug Reference Sheet: Combination Trastuzumab and Hyaluronidase-Oysk

A new product that combines trastuzumab and hyaluronidase (Herceptin Hylecta™) received U.S. Food and Drug Administration approval in February 2019 for the treatment of HER2-overexpressing breast cancer. The approval was based on the results of two randomized trials: HannaH and SafeHER.

Which Ambulatory Infusion Pump Is Best for 5-FU?

Because of its long infusion time over 46–48 hours, 5-fluorouracil (5-FU) is usually administered with an ambulatory infusion pump in the outpatient setting. However, two types of pumps exist. On one side of the spectrum is the elastomeric pump: small, compact, but gets the job done. On the other is the electronic pump: bigger, flashy, with lots of bells and whistles (literally). Here are the advantages and disadvantages of each.

Study Finds Three Priority Steps to Improve Cancer Survivorship

Healthcare providers need to address three priority areas to improve outcomes for cancer survivors and support caregivers for patients with cancer, according to findings from an evidence review published in CA: A Cancer Journal for Clinicians.

January 23, 2019

Current page 1
Page 2
Next page
Last page

To discuss the information in this article with other oncology nurses, visit the ONS Communities.

To report a content error, inaccuracy, or typo, email pubONSVoice@ons.org.

Chelsea Backler MSN, APRN, AGCNS-BC, AOCNS®, VA-BC

News, Views, and Advocacy From the Oncology Nursing Society

Legal Notices

Contact Us

Conferences

Advertising

Newsroom

Sitemap

Oncology Nursing Foundation

© Copyright 2022 Oncology Nursing Society

Back to Top ▲